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Introduction: Epidemiological analysis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in pediatric 
hematology and oncology (PHO) and hematopoietic cell transplant (HCT) centers in a Polish nationwide study, as well as analysis of 
the preventive strategies in these centers. Methods: All of the 18 PHO/HCT centers participated in eight surveys and questionnaires 
conducted over the first 5 months of the SARS-CoV-2/ coronavirus disease 2019 (COVID-19) pandemic in Poland. Epidemiological data 
were collected at eight regular time points, and the strategy of preventive management was done once after 4 months of the pandemic. 
Results: During this analyzed period, eight patients were positive for SARS-CoV-2. The estimated incidence of SARS-CoV-2 positivity in 
Polish PHO/HCT centers was 0.5%. After exclusion of HCT patients (with one patient being infected), the estimated incidence of SARS-
CoV-2 positivity was between 0.5 and 0.6%. In all but one case, the course of COVID-19 was asymptomatic or mild, and it was moderate 
in one case. None of them developed SARS or respiratory insufficiency, none of them required treatment in the intensive care unit (ICU), 
and no patient died due to SARS-CoV-2 infection. As of July 1, parents staying in the hospital together with their children were regularly 
tested for the virus in 13 centers. Asymptomatic healthcare personnel were regularly tested for the virus in seven centers. Conclusions: 
The estimated incidence of SARS-CoV-2 infection among PHO/HCT patients is lower than in Western Europe; however, these patients 
cannot be regarded as a low-risk group. The low COVID-19 incidence should be interpreted as a result of strictly and continuously 
implemented detailed preventive measures in the PHO/HCT wards and in hospitals.
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    All rights reserved.
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Introduction
Infections with a new coronavirus severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) 
first started in the Chinese district of Wuhan, and then 
spread rapidly throughout the entire world. The World 
Health Organization (WHO) announced the pandemic 
on March 11, and called the disease as coronavirus 
disease 2019 (COVID-19). Several countries noted 
very high rates of deaths caused by severe acute 
respiratory syndrome (SARS) [1]. The Polish Ministry 
of Health announced the epidemic crisis situation on 
March 14, and epidemic on March 23, 2020. This 
pandemic caused an unprecedented situation and 
stress on the healthcare system in all countries. Patient 
groups at highest risk for severe disease included 
age, comorbidities, and predisposing conditions such 
as immune suppression [2, 3]. Thus, all patients 
undergoing anticancer and/or immunosuppressive 
therapy faced the risk of infection [4, 5] and potential 
severe disease course and complications [6, 7]. The 
objective of this study is epidemiological analysis 
of the incidence of infections with SARS-CoV-2 in 
pediatric hematology and oncology (PHO) centers in 
a Polish nationwide study, as well as analysis of the 
preventive strategies in these centers.
Methods
Study design
The study consisted of two parts: (1) epidemiological 
data at eight time points and (2) strategy of prevention 
and management (as of July 1). Epidemiological data 
were regularly collected in eight time points between 
March 1 and August 1, initially on a 2-week basis, 
then from June 1, on monthly reports. The following 
data were collected: the number of patients at risk 
(on intensive chemotherapy, on immunosuppression, 
requiring visits in hospital); number of patients tested 
for SARS-CoV-2; number of patients positive for 
SARS-CoV-2; number of patients with SARS-CoV-2 
requiring therapy in the intensive care unit (ICU); and 
number of patients who died due to SARS-CoV-2. To 
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assess each center’s strategy on testing parents staying with children 
in the hospital as well as medical staff (physicians and nurses) in the 
PHO ward, an additional questionnaire was conducted reporting the 
status as on July 1.
Participating centers
Children with oncological diseases in Poland are treated in 18 centers 
accredited by the Polish Society of Pediatric Oncology and Hematology. 
One center is split into two separate departments, and since both are 
located in the same building, they were calculated as one. In six centers, 
hematopoietic cell transplant (HCT) units are included.
Patients at risk
In Poland, approximately 1,100–1,200 children are diagnosed 
with malignant disease annually [8]. The total number of beds in 
Polish hemato-oncological and/or transplant pediatric centers is 
725, including 50 transplant units (single bed units only). Daily, an 
average number of hospitalized cancer patients, including children 
undergoing or after transplantation is 450, 1,100–1,200 monthly 
with an average of 100 newly diagnosed patients each month. The 
inaccuracy of estimation is below 10% (data not published, collected 
in July–August 2019 by the National Consultant in pediatric oncology 
and hematology).
Testing for SARS-CoV-2
Tests were based on molecular testing by real-time polymerase chain 
reaction (RT-PCR) of a specimen obtained from naso-pharyngeal 
swabs. Cases were analyzed in regional laboratories, designated 
and specified by the health authority.
Definitions
•  Patient at risk: patients with a diagnosis of malignancy being on 
intensive chemotherapy (including periods off chemotherapy) or 
patients after hematopoietic cell transplantation at any phase 
being on immunosuppression or requiring visits to hospital.
•  Clinical course of COVID-19 was determined according to Dong 
et al. [9] (Tab. I).
Bioethical issues
The study was performed in accordance with the medical principles 
of the Declaration of Helsinki and Good Clinical Practice guidelines. 
All participants of the survey are coauthors of this manuscript and 
gave their agreement for publication.
Results
Epidemiological data
With the announcing of the epidemic in Poland (March 23), the 
epidemiological analysis for incidence of SARS-CoV-2 positivity 
was performed in PHO centers among patients at risk, respectively, 
for 2-week or 1-month periods (Tab. II). Only 14 patients were 
tested by March 23, and 72 patients by April 5. The testing was 
quickly available in most of the centers, and by June 1, already 
15/18 centers were able to test all patients admitted to the hospital 
(with some exceptions for 1-day treatments). During the analyzed 
period of 5 months, the overall number of estimated patients was 
1,124 (ranging 1,073–1,233). During this period, the total number 
of patients diagnosed for SARS-CoV-2 positivity was eight (Tab. III). 
Thus, with the estimated total number of patients at risk at 1,500–
1,600, the estimated incidence of SARS-CoV-2 positivity in Polish 
PHO/HCT centers was 0.5%. After exclusion of HCT patients (with 
one patient being infected), the estimated incidence of SARS-CoV-2 
positivity is between 0.5 and 0.6%. As of July 1, parents staying in the 
hospital together with their children were regularly tested for the virus 
in 13 centers. Asymptomatic healthcare personnel were regularly 
tested for the virus in seven centers.
Patients diagnosed positively for SARS-CoV-2
Patient 1: 9-year-old girl, with relapsed acute lymphoblastic leukemia 
(ALL), after total body irradiation (TBI) and hematopoietic cell 
transplantation from matched unrelated donor (MUD-HCT), diagnosed 
on day +7 during neutropenia, had mild respiratory symptoms. She 
was treated with chloroquine, ribavirin, and azithromycin. After 
granulocyte recovery on day +14, she recovered and was negative 
for SARS-CoV-2 twice after 7 and 8 days from diagnosis.
Patient 2: 5-year-old boy, with ALL, on chemotherapy (AIEOP-
BFM-2017, protocol II), hospitalized in the Department of Infectious 
Diseases with suspicion of encephalitis due to neurological 
symptoms (hemiparesis, facial nerve palsy, convulsions), and 
lung multiple nodules. Initially, tests for SARS-CoV-2 were 
negative twice, then positive (within 1 week from first symptoms). 
Table I. Clinical course of COVID-19 [9]
Clinical course Description
Asymptomatic Course without presence of any clinical symptoms and 
signs. Chest imaging normal. Polymerase chain reaction 
(PCR) test for SARS-CoV-2 positive
Mild Symptoms of current acute upper respiratory tract 
infection, usually including fever, fatigue, cough, 
myalgia, sore throat, sneezing, and runny nose. Physical 
examination: congestion of the pharynx, no auscultory 
abnormalities. Sometimes no fever is seen. Possibly, only 
gastro-intestinal tract symptoms may be present: nausea, 
vomiting, diarrhea, abdominal pain
Moderate Pneumonia, usually fever and dry cough, followed by 
possibly productive cough, even with wheezing is seen. 
No evident hypoxemia is present. Some cases may 
exceptionally have no clinical signs and symptoms, 
and only chest computed tomography (CT) shows lung 
lesions
Severe Early severe respiratory symptoms such as fever and 
cough, sometimes accompanied by diarrhea or other 
gastrointestinal symptoms. Usually in the second week, 
the disease progresses to dyspnea and central cyanosis. 
Hypoxia is present, with oxygen saturation below 92%
Critical Patients progress to severe acute respiratory distress 
syndrome (ARDS) and respiratory failure. Septic shock and 
life-threatening organ dysfunction can occur, including 
encephalopathy, acute kidney injury, heart failure, 
myocardial injury, or coagulation dysfunction
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Cerebrospinal (CNS) fluid was normal. No respiratory insufficiency 
occurred and he finally recovered after 40 days; however, the last 
lung computed tomography (CT) performed 100 days from COVID-19 
diagnosis revealed an increasing number of nodules along with 
persisting, but less pronounced fibrotic streaks, consolidation and 
discreet ground-glass opacities.
Patient 3: 5-year-old girl, with relapsed Wilms Tumor, immediately 
after cessation of therapy was asymptomatic, and did not require 
hospital treatment.
Patient 4: 12-year-old boy, with Down syndrome, treated for relapsed 
ALL, had mild clinical course, and did not require hospital treatment.
Patient 5: 4.5-year-old boy, with Wilms Tumor, after preoperative 
chemotherapy and surgery, was asymptomatic, and did not require 
additional hospital treatment.
Patient 6: 4.5-year-old old boy, treated with chemotherapy for CNS 
tumor, was asymptomatic, and did not require hospital treatment.
Patient 7: 17-year-old, girl, treated for ALL on maintenance phase, 
with cough, olfactory, and taste disturbances was hospitalized in the 
Department of Infectious Diseases. She recovered after 14 days from 
the beginning of clinical symptoms.
Patient 8: 16-year-old, boy with osteosarcoma, during post-surgery 
chemotherapy, was hospitalized for fever and pneumonia with mild 
symptoms. He recovered after 10 days from clinical symptoms.
Strategic management of pandemic in the PHO centers
The strategic management of pandemic in the PHO/HCT centers 
was analyzed based on a questionnaire conducted on July 1, 
among the Heads of the respective departments. All 18 centers 
(including HCT wards) filled in the questionnaire fully. Infection with 
SARS-CoV-2 occurred in hospitalized patients in one center, in out-
patient patients in two centers, and in healthcare staff in one center. 
Hospitals implemented standard operating procedures (SOP) on 
prevention of infection as guidelines for personnel in all 18 centers, 
triage of patients in all 18 centers, and temperature measurements 
in all 18 centers. Additional preventive procedures were implemented 
in the PHO departments for patients and personnel. Phone triage 
was done in 14 centers, and testing for SARS-CoV-2 by PCR in 
15 centers. Personnel rotation in various forms was performed 
in 13 centers and healthcare personnel testing for SARS-CoV-2 
by PCR in 11 centers. The number of patients in PHO/HCT wards 
has decreased: the number of hospitalized patients decreased in 
11 centers, with an estimated median value of 30% (ranging 15–50%); 
the number of patients hospitalized on a 1-day basis decreased in 
8 centers, with an estimated median value of 50% (ranging 20–70%); 
and the number of out-patient patients decreased in 16 centers, with 
an estimated median value of 30% (ranging 20–100%). Additionally, 
one center reported 30% decreased accessibility to laboratory 
diagnostics, and two centers a 15–20% decrease in accessibility to 
imaging diagnostics. No center reported any decrease in accessibility 
to medicines during this period.
Discussion
This nationwide study of SARS-CoV-2/COVID-19 status in PHO/
HCT centers showed relatively low estimated incidence of SARS-
CoV-2 positivity and high rate of centers performing testing for virus 
for all patients and their parents, when admitted to hospital (excluding 
1-day hospitalization for chemotherapy, without overnight stay).
The estimated incidence of infection with SARS-CoV-2 ranged 
between 0.5 and 0.6% of all patients at risk in the PHO/HCT centers. 
This rate is slightly lower in comparison to the largest COVID-19 
database on PHO/HCT children run by the AIOEP/BFM consortium 
[10] (Ondrej Hrusak, personal communication, update open-online for 
participating centers), including over 6,700 patients. The incidence 
was in the range of 0.74–0.82%, including Polish patients. This 
difference in incidence can reflect two important factors. First, lower 
overall incidence and number of infected individuals in the general 
Polish population, in comparison to Western European countries. 
Second, specific contact restrictions and set of anti-infective 
approaches implemented in Polish PHO centers, immediately after 
a rise in the rate of SARS-CoV-2 infections in Western countries 
(particularly Italy) in the initial phase [7]. Based on the EBMT [6] 
and Italian [7] experiences, the Polish Society of Pediatric Oncology 
and Hematology announced a national recommendation for the 
COVID-19 prevention and control in the pediatric units of hematology 
and oncology, hematopoietic cell transplantation units, and the 
respective outpatient clinics [11].
A total number of eight PHO/HCT patients were infected with 
SARS-CoV-2, including one patient after HCT, infected during 
TBI conditioning regimen in another hospital. In all but one case 
the course of COVID-19 was asymptomatic or mild, and it was 
moderate in one case. None of them developed SARS or respiratory 
insufficiency, nor required treatment in the Intensive Care Unit, and 
no patient died due to SARS-CoV-2 infection. In the AIOEP/BFM 
consortium experience, the death rate was 4% (2/50 patients); both 
the deceased patients had co-infections with other viruses (influenza, 
parainfluenza, cytomegalovirus [CMV]).
As far as the practical aspects of preventive measures of infections 
with SARS-CoV-2 are concerned, the PHO/HCT wards and their 
hospitals implemented national regulations introduced by the 
government. In the majority of centers, additional testing of parents 
hospitalized with their children was also applied, and in half of the 
centers regular screening of healthcare personnel of PHO/HCT 
wards took place.











23-03-2020 1,073 14 0
05-04-2020 1,017 (34*) 72 2
19-04-2020 1,056 (47*) 292 0
03-05-2020 1,111 (51*) 544 1
17-05-2020 1,137 (55*) 834 2
01-06-2020 1,180 (78*) 974 0
01-07-2020 1,199 (69*) All patients in  
15 centers
0
01-08-2020 1,233 (56*) 944 3
* – HCT patients at risk, included in overall number of patients
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The majority of centers experienced a decrease in the number of 
patients admitted to the hospital, and almost all the centers in the out-
patient setting. This was largely dependent on practices implemented 
by hospitals to limit personal contacts and the use of phone triage. 
This approach significantly contributed to the low incidence of SARS-
CoV-2 infections. Fortunately, no increase in mortality of patients with 
malignant diseases or undergoing hematopoietic cell transplantation 
was reported during this period. This observation undoubtedly 
underlines a very high level of medical service in the PHO/HCT 
centers.
In conclusion, the estimated incidence of SARS-CoV-2 infection 
among PHO/HCT patients is lower than in Western Europe; however, 
these patients cannot be regarded as a low-risk group. The low 
COVID-19 incidence should be interpreted as a result of strictly and 
continuously implemented detailed preventive measures in PHO/
HCT wards and in hospitals.
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Table III. Clinical course in patients positive for SARS-CoV-2









1 9 F Mild 7 Chloroquine, 
azithromycin, 
ribavirin
No Relapsed ALL After MUD-HCT 
day+7
2 5 M Moderate (neurological 
symptoms and pneumonia)
18 No No ALL Intensive 
chemotherapy





4 12 M Asymptomatic 5 No Down syndrome Relapsed ALL Intensive 
chemotherapy
5 4.5 M Asymptomatic 21 No No Wilms Tumor Intensive 
chemotherapy 
(after surgery)
6 4.5 M Mild 14 Azithromycin No CNS Tumor Chemotherapy
7 17 F Mild 10 Azithromycin No ALL Maintenance 
chemotherapy
8 16 M Mild 14 Azithromycin No Osteosarcoma Post-surgery 
chemotherapy
Pt – patient number; yrs – years; ALL – acute lymphoblastic leukemia; CNS – central nervous system; MUD-HCT – hematopoietic cell transplantation from matched unrelated donor
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